Cover Image
市場調查報告書

全球遺傳基因檢驗市場:市場規模、策略、市場預測 (2016∼2020年)

The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020

出版商 Howe Sound Research 商品編碼 347846
出版日期 內容資訊 英文 225 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球遺傳基因檢驗市場:市場規模、策略、市場預測 (2016∼2020年) The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020
出版日期: 2016年05月02日 內容資訊: 英文 225 Pages
簡介

本報告提供全球各種遺傳基因檢驗的市場相關調查、遺傳基因檢驗定義和概要、產業結構、進入經營者的營業情況、市場成長的各種影響因素分析、企業及企業間主要的配合措施/發表/新聞、主要企業簡介、主要國家的遺傳基因檢驗的實施數量/價格/收益的變化與預測等彙整資料。

第1章 簡介、市場定義

  • 遺傳基因檢驗定義
  • 基因學的演進
  • 市場定義
  • 美國的醫療市場、實驗室篩檢:展望

第2章 市場概要

  • 進入經營者
    • 供應商:醫藥品
    • 獨立型實驗室 (特殊)
    • 獨立型實驗室 (國家、地區層級)
    • 獨立型實驗室 (分析)
    • 公共實驗室 (國家、地區層級)
    • 醫院實驗室
    • 診療所實驗室
    • DTC實驗室
    • 獨立型遺傳基因檢驗實驗室
    • 審核團體
  • 遺傳基因檢驗的類型、案例、討論
    • 胚胎著床前遺傳基因診斷
    • 產前診斷
    • 新生兒篩檢
    • 診斷檢驗
    • 電信業者檢驗
    • 預測、前驅症狀階段檢驗
    • 醫藥基因學
    • 鑑別
    • 親子鑑定
    • 祖先遺傳基因檢驗
  • 產業結構
    • 在醫院的檢驗的佔有率
    • 規模經濟
    • 診療所實驗室
    • 診療所、POC檢驗
  • 主要遺傳基因檢驗企業簡介
    • Roche Molecular Diagnostics
    • Illumina
    • Hologic
    • Agilent/Dako
    • Qiagen
    • Myriad Genetics
    • Becton, Dickinson & Co.
    • Abbott Laboratories
    • Cepheid
    • Genomic Health
    • Grifols
    • bioMerieux
    • Foundation Medicine
    • Agendia
    • Thermo Fisher
    • Signal Genetics LLC
    • Siemens Healthcare
  • 主要遺傳基因企業的市場佔有率:分析

第3章 市場趨勢

  • 成長推動因素
  • 阻礙成長要素
  • 測量化、自動化
  • 診斷技術的發展

第4章 近幾年的產業趨勢

  • 近幾年的產業趨勢的重要性
  • Genomic Vision:與University-Hospital Institute Imagine策略性聯盟
  • Transgenomic:GAP商務單位的出售完畢
  • Cigna:發行Coverage Criteria for Whole-Exome Sequencing等
  • Admera Health:發表CardioGxOne Panel
  • 外顯子組測序的RTTN突然變異和原發性小頭症、小人症的相關研究
  • 新生兒的全基因測序等

第5章 各國市場:北美

  • 美國
  • 加拿大
    • 產前、新生兒檢驗的數量、價格、收益
    • 預測檢驗的數量、價格、收益
    • 藥理基因檢驗的數量、價格、收益
    • 全部的遺傳基因檢驗的數量、價格、收益

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 歐洲的其他地區、舊蘇聯
    • 產前、新生兒檢驗的數量、價格、收益
    • 預測檢驗的數量、價格、收益
    • 藥理基因檢驗的數量、價格、收益
    • 全部的遺傳基因檢驗的數量、價格、收益

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他地區
    • 產前、新生兒檢驗的數量、價格、收益
    • 預測檢驗的數量、價格、收益
    • 藥理基因檢驗的數量、價格、收益
    • 全部的遺傳基因檢驗的數量、價格、收益

第8章 各國市場:南美、中東

  • 巴西
  • 墨西哥
  • 其他地區
  • 非洲、中東
    • 產前、新生兒檢驗的數量、價格、收益
    • 預測檢驗的數量、價格、收益
    • 藥理基因檢驗的數量、價格、收益
    • 全部的遺傳基因檢驗的數量、價格、收益

第9章 全球市場的摘要

  • 全球市場
    • 產前、新生兒檢驗的數量、價格、收益
    • 預測檢驗的數量、價格、收益
    • 藥理基因檢驗的數量、價格、收益
    • 全部的遺傳基因檢驗的數量、價格、收益

第10章 遺傳基因檢驗的未來性

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Overview:

Will all newborns receive Whole Genomic Sequencing at birth?

Our facts and support = Your success.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2020. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes: B.Sc. (Chemistry) University of BC;M.B.A. (Finance and Policy) University of BC;Market Research Seminar - Burke Institute;Finance for Senior Executives - Harvard Business School.

Table of Contents

  • i. Genetic Testing Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Genetic Testing Definition
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing

2. Market Overview

  • 2.1 Market Participants
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Independent Genetic Testing Lab
    • 2.1.10 Audit body
  • 2.2 Genetic Tests - Types, Examples and Discussion
    • 2.2.1 Preimplantation Genetic Diagnosis
    • 2.2.2 Prenatal Diagnosis
    • 2.2.3 Newborn Screening
    • 2.2.2 Diagnostic Testing
    • 2.2.3 Carrier Testing
    • 2.2.6 Predictive and Presymptomatic Testing
    • 2.2.7 Pharmacogenomics
    • 2.2.8 Forensic Testing
    • 2.2.9 Parental Testing
    • 2.2.10 Ancestral Testing
    • 2.3 Industry Structure
    • 2.3.1 Hospital Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.2.1 Hospital vs. Central Lab
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT
  • 2.4 Profiles of Key Genetic Testing Companies
    • 2.4.1 Roche Molecular Diagnostics
    • 2.4.2 Illumina
    • 2.4.3 Hologic
    • 2.4.4 Agilent/Dako
    • 2.4.5 Qiagen
    • 2.4.6 Myriad Genetics
    • 2.4.7 Becton, Dickinson & Co.
    • 2.4.8 Abbott Laboratories
    • 2.4.9 Cepheid
    • 2.4.10 Genomic Health
    • 2.4.11 Grifols
    • 2.4.12 bioMérieux
    • 2.4.13 Foundation Medicine
    • 2.4.14 Agendia
    • 2.4.15 Thermo Fisher
    • 2.4.16 Signal Genetics LLC
    • 2.4.17 Siemens Healthcare
  • 2.5 Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Genetic Discovery Creates New Diagnostic Markets
    • 3.1.2 Aging Population a Boon for Diagnostics.
    • 3.1.3 Pharmacogenomics Drives Further Growth.
    • 3.1.4 Point of Care Testing can increase demand
    • 3.1.5 Fertility Practice
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs.
    • 3.2.3 Testing usage analysis curtailing growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 POCT/Self Testing Disruptive Force
    • 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5 CGES Testing, A Brave New World
    • 3.4.6 Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • 4.2 Genomic Vision Forms Strategic Partnership with University-Hospital Institute Imagine
  • 4.3 Transgenomic Completes Sale of GAP Business Unit
  • 4.4 Cigna Issues Coverage Criteria for Whole-Exome Sequencing; WGS Still Not Covered
  • 4.5 Exome Sequencing Links RTTN Mutation to Primary Microcephaly, Primordial Dwarfism
  • 4.6 Admera Health Announces CardioGxOne Panel
  • 4.7 Newborns to Get Whole Genome Sequencing
  • 4.8 Eurofins Acquiring PerkinElmer's NTD Laboratory Services Business
  • 4.9 GeneInsight Acquisition Boosts Sunquest's Clinical Genetics IT Platform
  • 4.10 AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
  • 4.11 The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics
  • 4.12 Research Validates Preimplantation Genetic Diagnosis for Aneuploidy (PGD-A)
  • 4.13 New Investments in Ancestry.com to Boost DNA Business
  • 4.14 GHO Capital Announces Acquisition of DNA Diagnostics Center
  • 4.48 Transgenomic Closes Public Offering of Stock, Warrants
  • 4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
  • 4.51 GenomeDx Biosciences Implements Clarity LIMS
  • 4.52 Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.53 Lifecode Receives CAP Accreditation, Discloses Funding
  • 4..54 Baylor College of Medicin, Miraca Holdings finalize joint venture.
  • 4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
  • 4.57 Trinity Biotech Revenues Grow by 15%
  • 4.58 Google's Latest Healthcare Initiative
  • 4.60 Agena Bioscience Launches Smaller Format MassArray
  • 4.61 QuantRx® Biomedical Provides Update on Technological Progress
  • 4.62 The Journal of Molecular Diagnostics Publishes Special Article
  • 4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
  • 4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
  • 4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
  • 4.66 Nuclea Bio Plans Entry into Clinical Proteomics
  • 4.67 Personal Genome Diagnostics Aims for FDA Clearance
  • 4.68 Enzo Biochem Announces New Molecular Platform
  • 4.69 Multiplicom, Premaitha Develop CE-IVDs
  • 4.70 Regulating the Next Generation of Genetic Testing
  • 4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
  • 4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
  • 4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
  • 4.74 Accelerate Diagnostics' 2014 Revenues Rise Sharply
  • 4.75 NanoString's Q4 Revenues Jump 54 Percent
  • 4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
  • 4.77 HTG Molecular Reports 50 Percent Increase in 2014 Revenues
  • 4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
  • 4.81 ACT Genomics Raises $8M in Private Funding Round
  • 4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
  • 4.83 Invitae Goes Public with $101.6M Offering
  • 4.84 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
  • 4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
  • 4.86 Premaitha Iona NIPT Lands CE Mark
  • 4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
  • 4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
  • 4.89 Invitae Amends IPO Filing Targeting up to $92.3M
  • 4.90 Biofortuna Closes $2.2M Funding Round
  • 4.91 Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
  • 4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
  • 4.93 BioMerieux 2014 Revenues Increase 7 Percent
  • 4.94 Cypher Genomics and Sequenom Announce Development Agreement
  • 4.95 Abcam to Acquire Firefly BioWorks for $28M
  • 4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
  • 4.98 GenMark Projects 52 Percent Growth in Q4 Revenues
  • 4.99 Amarantus Acquires DioGenix for up to $10.9M
  • 4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
  • 4.101 DiaCarta Raises $8M in Series A Round
  • 4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
  • 4.103 Adaptive Biotechnologies Acquires Sequenta
  • 4.104 Aegis Sciences Acquires MDx Firm Diagnovus
  • 4.105 Interleukin Genetics Secures $10M in Financing
  • 4.106 Premaitha NIPT Test Receives ISO Certification
  • 4.107 HTG Molecular Diagnostics Files for IPO of up to $60M
  • 4.108 CardioDx Raises $35M
  • 4.109 MolecularMD Receives CAP Accreditation
  • 4.110 14M Genomics Secures £12.5M Equity Financing for Oncology Dx
  • 4.111 Protagen Closes First Part of Financing Round
  • 4.112 Glyconics Inks Exclusive Licensing Deal
  • 4.113 Great Basin Scientific Begins Trial for Staph Assay
  • 4.114 Response Genetics Receives NYS Approval for Cancer Test
  • 4.115 Claritas Genomics Adopts NextCode Health Platform to Interpret NGS Tests
  • 4.116 FDA Clears Quidel's MDx for Bordetella Pertussis
  • 4.117 FDA Clears Additional Flu Strains for Focus' MDx Assay
  • 4.118 Novacyt Raises $3.8M in Private Equity
  • 4.119 Good Start Genetics Licenses PGS Technology from Johns Hopkins
  • 4.120 Metamark's Cambridge Lab Receives CAP Accreditation
  • 4.121 Australia's VCGS Inks Deal with Illumina to Develop NIPT
  • 4.123 Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton
  • 4.124 Roche to Acquire Ariosa Diagnostics

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 5.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.1.3 Pharmacogenomic Testing - Volumes, Prices, Revenues
    • 5.1.4 All Genetic testing - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 5.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 5.2.4 All Genetic testing - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.1.4 All Genetic testing - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.2.4 All Genetic testing - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.3.4 All Genetic testing - Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.4.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.4.4 All Genetic testing - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.5.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.5.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.5.4 All Genetic testing - Volumes, Prices, Revenues
  • 6.6 Russia
    • 6.6.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.6.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.6.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.6.6 All Genetic testing - Volumes, Prices, Revenues
  • 6.7 Remainder of Europe and Former Soviet Union
    • 6.7.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.7.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.7.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.7.4 All Genetic testing - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.1.4 All Genetic testing - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.2.4 All Genetic testing - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.3.4 All Genetic testing - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.4.4 All Genetic testing - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.5.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.5.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.5.4 All Genetic testing - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.6.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.6.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.6.6 All Genetic testing - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil
    • 8.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.1.4 All Genetic testing - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.2.6 All Genetic testing - Volumes, Prices, Revenues
  • 8.3 Rest of Latin America
    • 8.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.3.4 All Genetic testing - Volumes, Prices, Revenues
  • 8.4 Africa & The Middle East
    • 8.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.4.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.4.4 All Genetic testing - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global Market
    • 9.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 9.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 9.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 9.1.6 All Genetic testing - Volumes, Prices, Revenues

10. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2016 laboratory Fees Schedule - National Limit Midpoint

II Methodology

  • II.1 Authors
  • II.2 Sources

Table of Tables

  • Table 1: Most Common Traditional Genetic Disorders
  • Table 2: Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 3: Market Players by Type
  • Table 4: The Different Types of Genetic Tests
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: USA Prenatal and Newborn - Volume Price and Revenue Forecast
  • Table 10: USA Predictive - Volume Price and Revenue Forecast
  • Table 11: USA Pharmacogenomic Testing - Volume Price and Revenue Forecast
  • Table 12: USA All Genetic testing - Volume Price and Revenue Forecast
  • Table 13: Canada Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 14: Canada Predictive Testing - Volume Price and Revenue Forecast
  • Table 15: Canada Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 16: Canada All Genetic testing - Volume Price and Revenue Forecast
  • Table 17: France Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 18: France Predictive Testing - Volume Price and Revenue Forecast
  • Table 19: France Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 20: France All Genetic testing - Volume Price and Revenue Forecast
  • Table 21: Germany Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 22: Germany Predictive Testing - Volume Price and Revenue Forecast
  • Table 23: Germany Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 24: Germany All Genetic testing - Volume Price and Revenue Forecast
  • Table 25: U.K. Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 26: U.K. Predictive Testing - Volume Price and Revenue Forecast
  • Table 27: U.K. Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 28: U.K. All Genetic testing - Volume Price and Revenue Forecast
  • Table 29: Spain Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 30: Spain Predictive Testing - Volume Price and Revenue Forecast
  • Table 31: Spain Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 32: Spain All Genetic testing - Volume Price and Revenue Forecast
  • Table 33: Italy Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 34: Italy Predictive Testing - Volume Price and Revenue Forecast
  • Table 35: Italy Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 36: Italy All Genetic testing - Volume Price and Revenue Forecast
  • Table 37: Russia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 38: Russia Predictive Testing - Volume Price and Revenue Forecast
  • Table 39: Russia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 40: Russia All Genetic testing - Volume Price and Revenue Forecast
  • Table 41: Rest of Europe Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 42: Rest of Europe Predictive Testing - Volume Price and Revenue Forecast
  • Table 43: Rest of Europe Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 44: Rest of Europe All Genetic testing - Volume Price and Revenue Forecast
  • Table 45: China Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 46: China Predictive Testing - Volume Price and Revenue Forecast
  • Table 47: China Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 48: China All Genetic testing - Volume Price and Revenue Forecast
  • Table 49: Japan Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 50: Japan Predictive Testing - Volume Price and Revenue Forecast
  • Table 51: Japan Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 52: Japan All Genetic testing - Volume Price and Revenue Forecast
  • Table 53: South Korea Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 54: South Korea Predictive Testing - Volume Price and Revenue Forecast
  • Table 55: South Korea Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 56: South Korea All Genetic testing - Volume Price and Revenue Forecast
  • Table 57: India Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 58: India Predictive Testing - Volume Price and Revenue Forecast
  • Table 59: India Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 60: India All Genetic testing - Volume Price and Revenue Forecast
  • Table 61: Australia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 62: Australia Predictive Testing - Volume Price and Revenue Forecast
  • Table 63: Australia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 64: Australia All Genetic testing - Volume Price and Revenue Forecast
  • Table 65: Rest of Asia Pacific Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 66: Rest of Asia Pacific Predictive Testing - Volume Price and Revenue Forecast
  • Table 67: Rest of Asia Pacific Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 68: Rest of Asia Pacific All Genetic testing - Volume Price and Revenue Forecast
  • Table 69: Brazil Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 70: Brazil Predictive Testing - Volume Price and Revenue Forecast
  • Table 71: Brazil Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 72: Brazil All Genetic testing - Volume Price and Revenue Forecast
  • Table 73: Mexico Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 74: Mexico Predictive Testing - Volume Price and Revenue Forecast
  • Table 75: Mexico Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 76: Mexico All Genetic testing - Volume Price and Revenue Forecast
  • Table 77: Rest of Latin America Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 78: Rest of Latin America Predictive Testing - Volume Price and Revenue Forecast
  • Table 79: Rest of Latin America Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 80: Rest of Latin America All Genetic testing - Volume Price and Revenue Forecast
  • Table 81: Africa & Middle East Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 82: Africa & Middle East Predictive Testing - Volume Price and Revenue Forecast
  • Table 83: Africa & Middle East Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 84: Africa & Middle East All Genetic testing - Volume Price and Revenue Forecast
  • Table 85: Global Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 86: Global Predictive Testing - Volume Price and Revenue Forecast
  • Table 87: Global Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 88: Global All Genetic testing - Volume Price and Revenue Forecast
  • Table 89: 2016 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2: Chart of Market Shares of Key Genetic Companies
  • Figure 3: Percentage of World Population Over 65
Back to Top